NASDAQ:PEPG PepGen (PEPG) Stock Forecast, Price & News $12.28 -4.11 (-25.08%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$11.95▼$16.3950-Day Range$9.27▼$16.3952-Week Range$4.32▼$20.00Volume213,035 shsAverage Volume52,558 shsMarket Capitalization$292.02 millionP/E RatioN/ADividend YieldN/APrice Target$27.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media PepGen MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside119.9% Upside$27.00 Price TargetShort InterestHealthy1.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.29Based on 5 Articles This WeekInsider TradingSelling Shares$181,382 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.29) to ($3.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector541st out of 987 stocksPharmaceutical Preparations Industry254th out of 478 stocks 3.5 Analyst's Opinion Consensus RatingPepGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.00, PepGen has a forecasted upside of 119.9% from its current price of $12.28.Amount of Analyst CoveragePepGen has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.08% of the float of PepGen has been sold short.Short Interest Ratio / Days to CoverPepGen has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in PepGen has recently decreased by 5.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPepGen does not currently pay a dividend.Dividend GrowthPepGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PEPG. Previous Next 0.9 News and Social Media Coverage News SentimentPepGen has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for PepGen this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PepGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $181,382.00 in company stock.Percentage Held by InsidersOnly 3.97% of the stock of PepGen is held by insiders.Percentage Held by Institutions71.47% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for PepGen are expected to decrease in the coming year, from ($3.29) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PepGen is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PepGen is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPepGen has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About PepGen (NASDAQ:PEPG) StockPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.Read More Receive PEPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter. Email Address PEPG Stock News HeadlinesJune 8, 2023 | americanbankingnews.comJames G. Mcarthur Sells 1,800 Shares of PepGen Inc. (NASDAQ:PEPG) StockMay 31, 2023 | msn.comWedbush Reiterates PepGen (PEPG) Outperform RecommendationJune 10, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 31, 2023 | finance.yahoo.comPepGen (PEPG) Down on Clinical Hold for DM1 CandidateMay 30, 2023 | marketwatch.comPepGen Shares Tumble 18.4% After FDA Issues Hold Notice on StudyMay 30, 2023 | finance.yahoo.comPepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)May 19, 2023 | seekingalpha.comPepGen gets Health Canada nod to start trial of PGN-EDO51 for DMDMay 18, 2023 | finance.yahoo.comPepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular DystrophyJune 10, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 16, 2023 | americanbankingnews.comPepGen Inc. (NASDAQ:PEPG) Expected to Earn FY2027 Earnings of $0.29 Per ShareMay 16, 2023 | americanbankingnews.comEquities Analysts Set Expectations for PepGen Inc.'s Q1 2024 Earnings (NASDAQ:PEPG)May 12, 2023 | msn.comHC Wainwright & Co. Reiterates PepGen (PEPG) Buy RecommendationMay 12, 2023 | marketwatch.com10-Q: PEPGEN INC.May 11, 2023 | de.investing.comPepGen: EPS übertrifft Schätzungen um 0,14$ - Umsatz wie erwartetMay 11, 2023 | msn.comPepGen: Q1 Earnings InsightsMay 11, 2023 | finanznachrichten.dePepGen Inc.: PepGen Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsMay 11, 2023 | finance.yahoo.comPepGen Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsMay 4, 2023 | finance.yahoo.comPepGen to Participate in the Bank of America Securities 2023 Healthcare ConferenceApril 30, 2023 | americanbankingnews.comShort Interest in PepGen Inc. (NASDAQ:PEPG) Declines By 13.0%April 17, 2023 | finance.yahoo.comPepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual MeetingApril 13, 2023 | finance.yahoo.comPepGen to Participate in the 22nd Annual Needham Virtual Healthcare ConferenceApril 3, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on PepGen Inc. (PEPG)April 3, 2023 | americanbankingnews.comPepGen (NASDAQ:PEPG) Stock Rating Reaffirmed by HC WainwrightMarch 27, 2023 | finance.yahoo.comPepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call TranscriptMarch 27, 2023 | americanbankingnews.comPepGen (NASDAQ:PEPG) Earns "Buy" Rating from HC WainwrightMarch 27, 2023 | americanbankingnews.comPepGen (NASDAQ:PEPG) Price Target Raised to $22.00 at WedbushMarch 23, 2023 | benzinga.comPepGen Stock (NASDAQ:PEPG), DividendsSee More Headlines PEPG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PEPG Company Calendar Last Earnings5/11/2023Today6/09/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PEPG CUSIPN/A CIK1835597 Webwww.pepgen.com Phone781-797-0979FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$27.00 High Stock Price Forecast$33.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+119.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.94% Return on Assets-31.33% Debt Debt-to-Equity RatioN/A Current Ratio9.35 Quick Ratio9.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.60 per share Price / Book1.62Miscellaneous Outstanding Shares23,780,000Free Float22,838,000Market Cap$292.02 million OptionableNot Optionable BetaN/A Key ExecutivesDr. James G. McArthur Ph.D. (Age 61)Pres, CEO, Treasurer, Sec. & Director Comp: $597.95kMs. Caroline Godfrey Ph.D.Founder & Scientific Advisory Board MemberMr. Noel Donnelly M.B.A. (Age 53)Chief Financial Officer Comp: $519.65kDr. Jaya Goyal Ph.D. (Age 55)Exec. VP of Research & Preclinical Devel. Comp: $558.4kDr. Michael GaitFounder & Scientific Advisory Board MemberDr. Sonia Bracegirdle DPHIL (Age 37)Sr. VP of Strategy & Operations Ms. Jennifer CormierSr. VP of Clinical OperationsDr. Michelle L. Mellion M.D. (Age 47)Sr. VP & Head of Clinical Devel. Mr. Niels Svenstrup Ph.D. (Age 53)Sr. VP of Chemistry, Manufacturing & Control Mr. Kyle BreidenstineVP of Fin. & ControllerMore ExecutivesKey CompetitorsMarinus PharmaceuticalsNASDAQ:MRNSOculisNASDAQ:OCSNuvation BioNYSE:NUVBBelite BioNASDAQ:BLTEEmergent BioSolutionsNYSE:EBSView All CompetitorsInsiders & InstitutionsJames G. McarthurSold 8,419 sharesTotal: $136,640.37 ($16.23/share)James G. McarthurSold 500 sharesTotal: $8,030.00 ($16.06/share)James G. McarthurSold 1,800 sharesTotal: $28,872.00 ($16.04/share)JPMorgan Chase & Co.Bought 3,771 shares on 5/18/2023Ownership: 0.052%New York State Common Retirement FundSold 1,748 shares on 5/18/2023Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions PEPG Stock - Frequently Asked Questions Should I buy or sell PepGen stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PepGen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEPG shares. View PEPG analyst ratings or view top-rated stocks. What is PepGen's stock price forecast for 2023? 3 analysts have issued 1 year price objectives for PepGen's stock. Their PEPG share price forecasts range from $22.00 to $33.00. On average, they predict the company's share price to reach $27.00 in the next year. This suggests a possible upside of 119.9% from the stock's current price. View analysts price targets for PEPG or view top-rated stocks among Wall Street analysts. How have PEPG shares performed in 2023? PepGen's stock was trading at $13.37 at the start of the year. Since then, PEPG stock has decreased by 8.2% and is now trading at $12.28. View the best growth stocks for 2023 here. When is PepGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our PEPG earnings forecast. How were PepGen's earnings last quarter? PepGen Inc. (NASDAQ:PEPG) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.79) by $0.10. What ETFs hold PepGen's stock? ETFs with the largest weight of PepGen (NASDAQ:PEPG) stock in their portfolio include Direxion mRNA ETF (MSGR) and iShares Neuroscience and Healthcare ETF (IBRN).iShares Biotechnology ETF (IBB). When did PepGen IPO? (PEPG) raised $126 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. What is PepGen's stock symbol? PepGen trades on the NASDAQ under the ticker symbol "PEPG." Who are PepGen's major shareholders? PepGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (10.98%), BlackRock Inc. (4.15%), Geode Capital Management LLC (1.02%), State Street Corp (0.87%), Bank of New York Mellon Corp (0.17%) and Charles Schwab Investment Management Inc. (0.16%). Insiders that own company stock include James G Mcarthur and Jaya Goyal. View institutional ownership trends. How do I buy shares of PepGen? Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PepGen's stock price today? One share of PEPG stock can currently be purchased for approximately $12.28. How much money does PepGen make? PepGen (NASDAQ:PEPG) has a market capitalization of $292.02 million. The company earns $-69,100,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. How can I contact PepGen? The official website for the company is www.pepgen.com. The company can be reached via phone at 781-797-0979 or via email at investors@pepgen.com. This page (NASDAQ:PEPG) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.